Emergent BioSolutions Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Emergent BioSolutions Inc. - overview
Established
1998
Location
Gaithersburg, MD, US
Primary Industry
Biotechnology
About
Founded in 1998 and based in Maryland, US, Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture, and commercialization of vaccines and therapeutics that prevent or treat disease. In September 2024, Oak Hill Advisors provided an up to USD 250 million credit facility to Emergent BioSolutions Inc. As of 2024, the company is led by its CEO and president, Joseph Papa.
The corporation is traded on the NYSE under the ticker symbol EBS. The company’s products include the ACAM2000®, ANTHRASIL®, BAT®, BioThrax®, CYFENDUS®, NARCAN® Nasal Spray, VIGIV®, and more. Emergent also provides a range of contract development and manufacturing services (CDMO) through Emergent Bioservices, helping partners develop, scale, and produce life-saving therapeutics and vaccines. In addition to product development, Emergent demonstrates a commitment to social responsibility through corporate and community giving initiatives, environmental sustainability efforts, and product donations.
The company also supports medical education and external research programs to further advance public health outcomes. The firm serves governments, healthcare providers, and global organizations in safeguarding public health. The organization plans to use the September 2024 financing to repay the company's existing senior term loan facility.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.emergentbiosolutions.com/
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Emergent BioSolutions Inc. - timeline of key events
Emergent BioSolutions Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | Emergent BioSolutions Inc. | - | ||||||||
| Trade Sale | Completed | PaxVax, Inc | - | ||||||||
| N/A | Completed | 7114 Geoffrey Way | - |
Displaying 1 - 3 of 3
Emergent BioSolutions Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.